Alvotech kynnir jákv
Alvotech kynnir jákvæða niðurstöðu virknirannsóknar á AVT03, fyrirhugaðri líftæknilyfjahliðstæðu við Prolia og Xgeva
July 02, 2024 09:00 ET | Alvotech
Jákvæðar niðurstöður rannsóknarinnar sýna sambærilega klíníska virkni AVT03 og samanburðarlyfsins Prolia (denosumab) í sjúklingum Endapunktur var einnig uppfylltur í tveimur klínískum rannsóknum þar...
Alvotech Announces P
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
July 02, 2024 09:00 ET | Alvotech
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...
Alvotech Announces P
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
July 02, 2024 09:00 ET | Alvotech
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...
Alvotech_logo.jpg
Alvotech Issues New Shares to Holders of Convertible Bonds
July 01, 2024 17:35 ET | Alvotech
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech_logo.jpg
Alvotech gefur út nýja hluti í skiptum fyrir breytileg skuldabréf
July 01, 2024 17:35 ET | Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gefið út nýja hluti í skiptum fyrir breytileg skuldabréf, sem upprunalega voru gefin út af Alvotech í nóvember og desember 2022 og voru með...
Alvotech_logo.jpg
Alvotech Issues New Shares to Holders of Convertible Bonds
July 01, 2024 17:35 ET | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated...
Alvotech_logo.jpg
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024 05:10 ET | Alvotech
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech_logo.jpg
Alvotech kynnir áætlaðar mettekjur og EBITDA framlegð á öðrum ársfjórðungi 2024
July 01, 2024 05:10 ET | Alvotech
Alvotech (NASDAQ: ALVO)  kynnti í dag eftirfarandi óendurskoðaða áætlun um rekstrarniðurstöðu annars ársfjórðungs og á fyrri helmingi ársins 2024. Reiknað er með mettekjum Alvotech frá upphafi á...
Alvotech_logo.jpg
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024 05:10 ET | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key...
Alvotech_logo.jpg
Eigendur meirihluta breytilegra skuldabréfa Alvotech nýta rétt til að breyta yfir í hlutabréf
June 26, 2024 04:50 ET | Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að eigendur meirihluta breytilegra skuldabréfa félagins sem upphaflega voru útgefin 16. nóvember og 20. desember 2022 með lokagjalddaga 20. desember 2025, hafi...